Abstract
Background: The Area Under the Concentration-time curve (AUC) of Mycophenolic Acid (MPA), is a valid prognosticator of the risk of rejection and the gold standard in its Therapeutic Drug Monitoring (TDM), over time post-transplantation.
Objective: This study aimed to investigate MPA pharmacokinetic parameters and develop a Limited Sampling Strategy (LSS) to estimate an abbreviated MPA AUC, in the stable phase post-renal transplantation.
Methods: In this study, 19 patients with normal graft function (glomerular filtration rate >70 ml/min) who fulfilled the inclusion and exclusion criteria were involved. Blood samples at various times were taken in the stable phase after transplantation. MPA plasma concentration was measured by reverse-phase high-performance liquid chromatography. MPA AUC0–12h was calculated using the linear trapezoidal rule. Multiple stepwise regression analysis was used to determine the minimal time points of MPA levels that could be used to yield model equations best fitted to MPA AUC 0-12h. The findings of this study were compared with the results of our previous study, which was done similarly in the early phase post-renal transplantation.
Results: The results demonstrated that the MPA-AUC and clearance were not affected over time, but MPA-tmax was significantly lower in the stable phase in comparison with the early phase (P=0.001). The best regression equation for AUC estimation in the stable phase was AUC=9.57*C6+27.238 (r2=0.907). The validation of the method was performed using the jackknife method. The mean prediction error of these models was not different from zero (P > 0.05) and had a high root mean square prediction error (7.91).
Conclusion: In conclusion, the pharmacokinetics of MPA could be affected by time after transplantation, making it essential to develop a limited sampling strategy as an efficacious approach for therapeutic drug monitoring during the stable post-transplant period.
Keywords: Kidney transplantation, mycophenolic acid, pharmacokinetics, renal, time, area under curve.
Graphical Abstract
Current Reviews in Clinical and Experimental Pharmacology
Title:Estimation of Abbreviated Mycophenolic Acid Area Under the Concentration- Time Curve during Stable Post-transplant Period by Limited Sampling Strategy
Volume: 16 Issue: 3
Author(s): Asieh Karimani, Hasan Abedi, Fatemeh Nazemian, Atena Poortaji and Amir Hooshang Mohammad Pour*
Affiliation:
- Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad,Iran
Keywords: Kidney transplantation, mycophenolic acid, pharmacokinetics, renal, time, area under curve.
Abstract:
Background: The Area Under the Concentration-time curve (AUC) of Mycophenolic Acid (MPA), is a valid prognosticator of the risk of rejection and the gold standard in its Therapeutic Drug Monitoring (TDM), over time post-transplantation.
Objective: This study aimed to investigate MPA pharmacokinetic parameters and develop a Limited Sampling Strategy (LSS) to estimate an abbreviated MPA AUC, in the stable phase post-renal transplantation.
Methods: In this study, 19 patients with normal graft function (glomerular filtration rate >70 ml/min) who fulfilled the inclusion and exclusion criteria were involved. Blood samples at various times were taken in the stable phase after transplantation. MPA plasma concentration was measured by reverse-phase high-performance liquid chromatography. MPA AUC0–12h was calculated using the linear trapezoidal rule. Multiple stepwise regression analysis was used to determine the minimal time points of MPA levels that could be used to yield model equations best fitted to MPA AUC 0-12h. The findings of this study were compared with the results of our previous study, which was done similarly in the early phase post-renal transplantation.
Results: The results demonstrated that the MPA-AUC and clearance were not affected over time, but MPA-tmax was significantly lower in the stable phase in comparison with the early phase (P=0.001). The best regression equation for AUC estimation in the stable phase was AUC=9.57*C6+27.238 (r2=0.907). The validation of the method was performed using the jackknife method. The mean prediction error of these models was not different from zero (P > 0.05) and had a high root mean square prediction error (7.91).
Conclusion: In conclusion, the pharmacokinetics of MPA could be affected by time after transplantation, making it essential to develop a limited sampling strategy as an efficacious approach for therapeutic drug monitoring during the stable post-transplant period.
Export Options
About this article
Cite this article as:
Karimani Asieh , Abedi Hasan , Nazemian Fatemeh, Poortaji Atena and Pour Hooshang Mohammad Amir *, Estimation of Abbreviated Mycophenolic Acid Area Under the Concentration- Time Curve during Stable Post-transplant Period by Limited Sampling Strategy, Current Reviews in Clinical and Experimental Pharmacology 2021; 16 (3) . https://dx.doi.org/10.2174/1574884715666200827104813
DOI https://dx.doi.org/10.2174/1574884715666200827104813 |
Print ISSN 2772-4328 |
Publisher Name Bentham Science Publisher |
Online ISSN 2772-4336 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Cell Signalling Mechanisms Involved in Differential Placental Angiogenesis in Mild and Severe Pre-Eclampsia
Current Vascular Pharmacology Genetics of Hypertrophic and Dilated Cardiomyopathy
Current Pharmaceutical Biotechnology Cyclooxygenase and Atherosclerosis: A Smoking Area
Current Pharmaceutical Design Approaching the Golden Age of Natural Product Pharmaceuticals from Venom Libraries: An Overview of Toxins and Toxin-Derivatives Currently Involved in Therapeutic or Diagnostic Applications
Current Pharmaceutical Design Genomics and Pharmacogenomics of Salt-sensitive Hypertension
Current Hypertension Reviews Renal Nerve Ablation for Hypertensive Patients with Chronic Kidney Disease
Current Vascular Pharmacology Neuroprotection and Behavior Regulation by Adrenomedullin and PAMP as Shown by Conditional Knockout Models
Current Hypertension Reviews Novel Carriers for Coenzyme Q10 Delivery
Current Drug Delivery Drugs for the Treatment of Hypercholesterolemia and their Benefits Beyond Cholesterol Lowering to Prevent Vascular Disease
Vascular Disease Prevention (Discontinued) Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets Hypertension, Nitric Oxide, Oxidants, and Dietary Plant Polyphenols
Current Pharmaceutical Biotechnology Prostacyclin, Atherothrombosis and Diabetes Mellitus: Physiologic and Clinical Considerations
Current Molecular Medicine Benign Prostatic Hyperplasia and Clinical Prostate Cancer - Two New Components of the Metabolic Syndrome
Current Hypertension Reviews Patent Selections
Recent Patents on Food, Nutrition & Agriculture Mitochondrial Oxidative Stress and Heart Failure ∼Novel Pathophysiological Insight and Treatment Strategies∼
Current Cardiology Reviews Recent Aspects of Osmotic Pump Systems: Functionalization, Clinical use and Advanced Imaging Technology
Current Drug Metabolism Interaction Between KATP-Channels and Protein Kinase C in the Regulation of Basal Coronary Flow
Vascular Disease Prevention (Discontinued) Safety of Therapeutics Used in Management of Patent Ductus Arteriosus in Preterm Infants
Current Drug Safety Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets Histone Methylation and Transcriptional Regulation in Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets